A new study commissioned by Malaria No More UK and conducted by Oxford Economics Africa reveals that reducing malaria by 90% by 2030 could significantly boost the economies of malaria-endemic countries by $142.7 billion.
This substantial economic benefit underscores the importance of investing in the fight against malaria.
Malaria not only affects health but also imposes a significant financial burden on families and communities, hindering economic progress globally.
The research highlights that achieving the Sustainable Development Goal of reducing malaria can generate an additional $31 billion in exports for the most affected countries in Africa.
It also forecasts economic boosts for G7 countries, with an almost $4 billion rise for the US and more than $450 million for the UK.
Dr. Astrid Bonfield, CEO of Malaria No More UK, emphasized the importance of increased investment in malaria eradication.
Bonfield said, “Investing more in the fight to end malaria can save millions of lives, grow the African economy, and boost trade.
This can unlock new funds to bolster health spending and strengthen health security in Africa and globally.
“The rise in global trade with Africa allows other nations to keep the disease at bay by sustaining malaria research and development funding.
“In a storm of global challenges, G7 and malaria-endemic countries can work hand in hand to drive greater investment in malaria through Gavi and The Global Fund.”
Nigeria, the most populous country in Africa, stands to benefit significantly. If malaria is reduced as per WHO goals, Nigeria’s GDP could increase by $34 billion by 2030.
The report from Oxford Economics Africa states that Africa would account for 88% of the cumulative $142.7 billion economic benefit expected by 2030.
Despite progress, malaria still causes over 600,000 deaths annually, primarily in sub-Saharan Africa.
The disease also keeps adults out of work and children out of school.
The report warns that maintaining the status quo will continue to cost lives and hinder economic progress due to lost income, absenteeism, and increased healthcare costs.
Recently approved malaria vaccines offer hope, with countries like Ghana, Cameroon, and Malawi already incorporating them into their immunization programs.
However, funding has dropped, and scientists are seeking new solutions to counter growing resistance to existing treatments.
